US › Healthcare

Corbus Pharmaceuticals Holding (CRBP)

US · Healthcare · Biotechnology

$4.52+4.39%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-35.0M

EPS

$-1.81

EPS estimate

$-1.30

EPS came in at -1.81 against a street estimate of -1.30 — a miss of 39.2%.

Key statistics

Market cap

$87.4M

Forward P/E

0.0

P/B

1.37

Book value

$5.48

EPS (TTM)

$-6.11

52-week high

$20.56

52-week low

$4.22

50-day MA

$8.32

200-day MA

$8.82

Beta

2.63

Analyst view

Analysts rate Corbus Pharmaceuticals Holding a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $34.02.

Shareholding

Insiders

1.24%

Institutions

83.77%

Largest institutional holders

Fund	Stake
Cormorant Asset Management, LLC	12.12%
Orbimed Advisors LLC	8.98%
BlackRock Inc	6.88%
Aberdeen Group PLC	6.83%
Vanguard Capital Management, LLC	3.93%
Jones Hill Capital LP	3.38%
Prosight Management, LP	3.36%
Stonepine Capital Management Llc	2.20%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Corbus Pharmaceuticals Holding — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.